Inhibition of interleukin-3-dependent growth of CD34+ acute myelogenous leukemia cells by recombinant soluble CD23.
Mossalayi
M D
MD
Immunology Department, Pitié-Salpêtrière Hospital, Paris, France.
Merle-Beral
H
H
Dalloul
A H
AH
Arock
M
M
Michel
A
A
Hofstetter
H
H
Debre
P
P
D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis* / Q000502:physiology*; D018952:Antigens, CD34; D000944:Antigens, Differentiation, B-Lymphocyte / Q000502:physiology*; D001853:Bone Marrow / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D006680:HLA Antigens / Q000032:analysis; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000494:pharmacology; D007377:Interleukin-3 / Q000494:pharmacology*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000473:pathology*; D010641:Phenotype; D011961:Receptors, Fc / Q000502:physiology*; D017455:Receptors, IgE; D011994:Recombinant Proteins / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018952:Antigens, CD34; D000944:Antigens, Differentiation, B-Lymphocyte; D006680:HLA Antigens; D007375:Interleukin-1; D007377:Interleukin-3; D011961:Receptors, Fc; D017455:Receptors, IgE; D011994:Recombinant Proteins